Rodman & Renshaw Downgrades Sirtris Pharmaceuticals (SIRT) to Market Perform
More News related to GSK
- GlaxoSmithKline (GSK) to Close U.K. Research Center - DJN
- Nabi Biopharma (NABI) Receives $8M Milestone from Glaxo (GSK) Regarding PentaStaph Vaccine
- GlaxoSmithKline (GSK) Reports Q4 Adj-EPS of 34.4P, vs. Consensus of 33.5P
- Trading Radar for 02/04: Bunge (BG), Spectra Energy (SE), MasterCard (MA), Con-Way (CNW), Hospira (HSP) Report
- Highlights From PFE's Q4 Conference Call: Wyeth Integration Going Well; Issues Guidance Through 2012
More News related to SIRT
- Notable Mergers and Acquisitions of the Day 6/6 (GSK/SIRT, CXO, GM)
- Following Today's Kosan (KOSN) Buyout, Investors Look for Next Biotech Deal
- Rodman & Renshaw Downgrades Sirtris Pharmaceuticals (SIRT) to Market Perform
- Biotech Merger Fever: Who's Next
- Unusual 11 Mid-Day Movers 4/23: SIRT, SAF, ZOLL, ANAD Higher; ABK, MBI, TSFG, DAKT Lower
More News related to Downgrades
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
- Stifel Nicolaus Downgrades Parkway Properties (PKY) to Sell
- Craig-Hallum Downgrades Terremark (TMRK) to Accumulate
Rodman & Renshaw downgrades Sirtris Pharmaceuticals (Nasdaq: SIRT) from Outperform to Market Perform, citing acquisition offer from Glaxo (NYSE: GSK).
Sirtris Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases, such as Type 2 Diabetes.
Related Categories
DowngradesStocks Mentioned
+0.35Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
